AstraZeneca PLC (AZN:LSE) Jefferies Financial LLC raises the target price to GBX 9800

STA Research
by: STA Research
AstraZeneca PLC

Jefferies Financial LLC maintains AstraZeneca PLC with a Buy rating and raises the target price to GBX 9800 from GBX 9500 on the company’s stock.

Based on the AstraZeneca PLC stock forecasts from 6 analysts, the average analyst target price for AstraZeneca PLC is GBX 9,650.00 over the next 12 months. AstraZeneca PLC’s average analyst rating is . Stock Target Advisor’s own stock analysis of AstraZeneca PLC is Slightly Bullish , which is based on 7 positive signals and 4 negative signals. At the last closing, AstraZeneca PLC’s stock price was GBX 11,004.00AstraZeneca PLC’s stock price has changed by +1.89% over the past week, +7.57% over the past month and +27.10% over the last year.

What we like:

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What we don’t like:

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Disclaimer

Stock Target Advisor is not a broker/dealer, investment advisor, or platform for making stock buying or selling decisions. Our goal is to democratize and simplify financial information through automated analysis, aggregation of stock information, and education to help investors with their research. No content on our site, blogs or newsletters constitutes – or should be understood as constituting – a recommendation to enter into any securities transactions or to engage in any of the investment strategies presented in our site content. We also cannot guarantee the accuracy of any information presented on our site and in our analysis.

Leave a Reply

Your email address will not be published.